Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 137
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | ||
| NCT04030845 | Patient Report Outcome-Reconstruction and Oncoplastic Cohort | ||
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | ||
| NCT02630108 | TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma | ||
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | ||
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC | ||
| NCT05079074 | Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer | ||
| NCT02448966 | Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy | ||
| NCT05955391 | TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | ||
| NCT04922450 | Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | ||
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | ||
| NCT06836869 | Modified Tumor-free Techniques Operation to Cervical Cancer | ||
| NCT05979961 | Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma | ||
| NCT07163481 | A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | ||
| NCT03097848 | Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma | ||
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | ||
| NCT05633914 | Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | ||
| NCT01470495 | Combined Treatment of RFA and Sorafenib on Recurrent HCC | ||
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | ||
| NCT07314216 | Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma | ||
| NCT05107011 | Phase I/II Clinical Trial of LBL-015 for Injection | ||
| NCT03637634 | The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study | ||
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | ||
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | ||
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | ||
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | ||
| NCT07237828 | Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR | ||
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | ||
| NCT05942768 | Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer | ||
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak | ||
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | ||
| NCT01271439 | Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma | ||
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | ||
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | ||
| NCT04414969 | Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma | ||
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | ||
| NCT05367739 | Real World Study on the Efficacy and Safety of Anti-HER2 Therapy | ||
| NCT06022770 | Clinical Study on Nutrition Intervention in Patients With Esophageal and Gastric Cancer Treated With Chemotherapy | ||
| NCT06830083 | Hypofractionated Radiation Fractionation in Breast Cancer Patients with Implant-Based Reconstruction | ||
| NCT06752798 | Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC | ||
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | ||
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | ||
| NCT05427617 | Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer | ||
| NCT02876861 | Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC | ||
| NCT04193319 | Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects | ||
| NCT03895788 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | ||
| NCT03351062 | Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | ||
| NCT06031376 | Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC | ||
| NCT06863506 | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC | ||
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy |
